Shenguan's main business is the manufacture and sale of edible collagen sausage products, pharmaceuticals, food, skincare and health products, and collagen medical devices. Edible collagen sausage products In fiscal year 2022 (“this period”), the Group will work on “stabilizing quality and expanding production capacity” in the collagen sausage industry. The Group continues to make stabilizing the quality of collagen sausage products a top priority. From production to sales, the Group implements a responsibility system and supervision system to ensure the normal operation of facilities and equipment and the correct production and operation methods to ensure product quality. The Group has completed a number of R&D and technological improvement projects, and through these projects, the Group will increase production capacity and reduce production costs without increasing space. In terms of internal management, the Group continues to strengthen management awareness and clarify management responsibilities, and implement strengthened supervision and standardized behavior. collagen food The Group's products include collagen rice noodles, collagen drinks, beef tenderloin and collagen oatmeal. In order to expand the product range, the Group has obtained a production license for collagen oat extract during this period, and has prepared various preparations for large-scale production. collagen skincare The Group has further improved the quality of skincare products, continuously upgraded product formulations, and changed its marketing methods according to market trends. It adopted online as the main and offline supplementary marketing method, which promoted the sale of products such as collagen masks, collagen extract, collagen extract, etc., and was gradually recognized by consumers. collagen medical devices Guangdong Shengchi Biotechnology Co., Ltd. (“Guangdong Shengchi”) and Wuzhou Shengchi Biotechnology Co., Ltd. (“Wuzhou Shengchi”) have both obtained EU ISO13485 and ISO22442 certifications. Medical collagen raw materials have been registered on corporate websites published by relevant departments in the country, which will help improve the feasibility of customers selecting the Group's medical collagen raw materials. “Collagen bone filler material (artificial bone)” has been approved by the Clinical Trial Ethics Committee, and clinical trials are being carried out in seven hospitals. The Group's production equipment for the Group's first-class medical device product “band-aid” has been installed and trial production has been successfully completed. It is applying for registration of a “disposable sterile bandage” for a Class II medical device product. “In-vivo absorbable hemostasis dressings” are undergoing animal testing and discussions on clinical trial plans, while “medical aesthetic products (small cosmetic needles)” have completed product development and are undergoing index testing before animal testing.
No Data
No Data